This study was designed to compare the neonatal abstinence syndrome (NAS) in neonates
of methadone and buprenorphine maintained pregnant opioid-dependent women and to …

Background Methadone, a full mu-opioid agonist, is the recommended treatment for opioid
dependence during pregnancy. However, prenatal exposure to methadone is associated …

Background Buprenorphine pharmacotherapy for opioid-dependent pregnant women is
associated with maternal and neonatal outcomes superior to untreated opioid dependence …

Aims This paper reviews the published literature regarding outcomes following maternal
treatment with buprenorphine in five areas: maternal efficacy, fetal effects, neonatal effects …

Neonates born to opioid-maintained mothers are at risk of developing neonatal abstinence
syndrome (NAS), which often requires pharmacological treatment. This study examined the …

Aims To compare the profile of signs of neonatal abstinence syndrome (NAS) in methadone‐
versus buprenorphine‐exposed infants. Design, setting and participants Secondary analysis …

OBJECTIVE: To compare neonatal abstinence syndrome prevalence and characteristics
among neonates born to women prescribed buprenorphine and naloxone compared with …

Given that buprenorphine+ naloxone is prescribed for opioid-dependent pregnant women, it
is important to examine the extent to which it differs from buprenorphine alone, methadone …

Aims More than half of infants exposed to opioids in utero develop neonatal abstinence
syndrome (NAS) of severity to require pharmacological therapy. Current treatments are …

Patients and methods In order to investigate the effects of exposure to buprenorphine
compared with methadone during pregnancy, a prospective multicenter study was …